Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
NEUROPHET Logo
NEUROPHET Growth Score
95
CB Rank
4190
Heat Score
85
NEUROPHET is a medical SW company using advanced neuroscience and AI technologies for better brain treatment.
Founded
obfuscation
PublicPost-IPO Equity Gangneung, Kangwon-do, South Korea51-100 www.neurophet.com/
Artificial Intelligence (AI)
Machine Learning
Medical
Neuroscience
Software
Overview

NEUROPHET
Total Funding
obfuscation
Growth Score
95
Heat Score
85

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score95
-1 pts
in past quarter
Heat Score 85
13 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
+5 more milestones
See more interactive data and historical milestones on desktop for the best experience

About NEUROPHET

CB Rank
4190
NEUROPHET is a medical SW company using advanced neuroscience and AI technologies for better brain treatment.
Founded
obfuscation
PublicPost-IPO Equity Gangneung, Kangwon-do, South Korea51-100 www.neurophet.com/
Artificial Intelligence (AI)
Machine Learning
Medical
Neuroscience
Software

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation
Corporate Round
OBF
in
obfuscation

Key People

  • Photo of Donghyeon Kim
    Donghyeon Kim: Co-CEO and Chief Technology Officer
    Past Role: NEUROPHET, Co-founder
  • Photo of Josh Cohen
    Josh Cohen: Head of Americas Business
    Past Role: Cortechs.ai, Chief Commercial Officer

Details

Legal Name Neurofit Co., Ltd
Also Known As 뉴로핏, 주식회사 뉴로핏
Operating Status Active
Stock Symbol  KOSDAQ:380550
Company Type For Profit
Founders  Donghyeon Kim, Jake Been
About the Company

Neurophet is a medical technology enterprise that focuses on neuro-engineering and brain health. The company develops software programs that utilize artificial intelligence for the analysis of medical brain images. The firm creates simulation tools specifically for medical researchers and doctors who perform non-invasive electrical brain

stimulation procedures. These applications allow medical professionals to generate three-dimensional models of individual human brains directly from magnetic resonance imaging data.

Phone Number +82 02-6954-7971
Contact Email contact@neurophet.com
Predictions & Insights

Growth Insight

See this Growth Insight
NEUROPHET is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Growth Prediction

See this Growth Prediction
Top Contributing Factors
Key Employee Changes

Products & Services

Neurophet AQUA AD Plus
Integrated AI brain imaging analysis software to support decision-making for Alzheimer’s disease therapies.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 9
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - NEUROPHET Logo
Post-IPO Equity - NEUROPHET
6
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NEUROPHET Logo
Post-IPO Equity - NEUROPHET
6
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NEUROPHET Logo
Post-IPO Equity - NEUROPHET
6
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NEUROPHET Logo
Post-IPO Equity - NEUROPHET
6
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NEUROPHET Logo
Post-IPO Equity - NEUROPHET
6
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 9
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - NEUROPHET Logo
Post-IPO Equity - NEUROPHET
6
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NEUROPHET Logo
Post-IPO Equity - NEUROPHET
6
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NEUROPHET Logo
Post-IPO Equity - NEUROPHET
6
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NEUROPHET Logo
Post-IPO Equity - NEUROPHET
6
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NEUROPHET Logo
Post-IPO Equity - NEUROPHET
6
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
FOCUS ASSET MANAGEMENT Logo
FOCUS ASSET MANAGEMENT
—
Post-IPO Equity - NEUROPHET Logo
Post-IPO Equity - NEUROPHET
—
FOCUS ASSET MANAGEMENT Logo
FOCUS ASSET MANAGEMENT
—
Post-IPO Equity - NEUROPHET Logo
Post-IPO Equity - NEUROPHET
—
FOCUS ASSET MANAGEMENT Logo
FOCUS ASSET MANAGEMENT
—
Post-IPO Equity - NEUROPHET Logo
Post-IPO Equity - NEUROPHET
—
FOCUS ASSET MANAGEMENT Logo
FOCUS ASSET MANAGEMENT
—
Post-IPO Equity - NEUROPHET Logo
Post-IPO Equity - NEUROPHET
—
FOCUS ASSET MANAGEMENT Logo
FOCUS ASSET MANAGEMENT
—
Post-IPO Equity - NEUROPHET Logo
Post-IPO Equity - NEUROPHET
—
Market Intelligence
People
View Profiles & Contacts
Headcount 51-100 Employee Profiles 3 Board Members and Advisors 1 Contacts 3

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 16, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 26, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 26, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 21, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

9,091
1.3%
 in past month

Active Website Tech Count

18NEUROPHET is actively using 18 technologies for its website, according to BuiltWith. These include HSTS, DNSSEC, and  U.S. Server Location.

Total IP

43The intellectual property of NEUROPHET includes 35 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, NEUROPHET has registered 8 trademarks with the most popular class being 'Scientific and electric apparatus and instruments', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is NEUROPHET's headquarters? NEUROPHET is located in Gangneung, Kangwon-do, South Korea.Who invested in NEUROPHET? NEUROPHET has 28 investors including FOCUS ASSET MANAGEMENT and  Findvalue Asset Management.When was the last funding round for NEUROPHET? NEUROPHET closed its last funding round on
obfuscation
from a Post-IPO Debt round.Who are NEUROPHET's competitors? Alternatives and possible competitors to NEUROPHET may include Aidoc, Qure AI, and  Brainomix.How much funding has NEUROPHET raised to date? NEUROPHET has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(c22f898 1)
|